The most consequential AI running right now is not writing your emails, generating your slide deck, or answering your customer support tickets. It is sitting inside a laboratory services company in Burlington, North Carolina, cross-referencing diagnostic results from millions of patients against medical claims data, looking for patterns in Alzheimer's disease progression that human researchers would take months to find on their own.

Last month, Labcorp announced an artificial intelligence-powered real-world data platform for Alzheimer's research, built with Amazon Web Services and Datavant. The headline was about speed: insights in minutes that previously required months of intensive data mining. The line that deserved more attention was buried in the boilerplate. Labcorp supported more than 85 percent of the new drugs and therapeutic products approved by the FDA in 2025. That is not a data services company. That is embedded infrastructure inside the global drug development pipeline.

I came to this story through Sri Elaprolu, Director at the AWS Generative AI Innovation Center, who has been running a LinkedIn series documenting real-world AI deployments. His post on the Labcorp platform stopped me. The case study deserved more analysis than a press release summary. Credit where it is due: Sri surfaces stories that most technology coverage misses.

I came to this story through Sri Elaprolu, Director at the AWS Generative AI Innovation Center, who runs a LinkedIn series documenting real-world AI deployments. His post on the Labcorp platform stopped me mid-scroll. The case study deserved more analysis than a press release summary. Credit where it is due: Sri consistently surfaces stories that most technology coverage misses.

This post is about the Labcorp story. But it is also about a broader argument I started making in an earlier post using a traffic intelligence platform in Cyberabad as the proof point: the AI categories doing the most important work for humanity are Analytical AI and Predictive AI. Generative AI dominates the conversation. The other two do the work.

Three Categories, One Hierarchy

The AI industry has a categorization problem. When most people use the word AI, they mean Generative AI: large language models, image generators, code assistants, chatbots. That category is real, useful, and commercially important. It is also the least likely to solve the problems that genuinely threaten human welfare at scale.

Analytical AI classifies and interprets data. It finds patterns, flags anomalies, segments populations, and gives researchers a picture of what is actually happening inside a dataset. Computer vision reading a traffic camera is Analytical AI. A diagnostic platform identifying Alzheimer's biomarker patterns across millions of lab results is Analytical AI.

Predictive AI uses that analysis to project forward. It models disease progression curves, forecasts which patient cohorts are likely to respond to a given treatment, identifies who should be enrolled in a clinical trial before the trial sponsor knows those patients exist. The time savings claimed by the Labcorp platform — months of data preparation compressed into minutes — are primarily Predictive AI doing the cohort identification work faster than any human team could.

Generative AI then translates findings into language researchers can act on, summarizes patterns, and assists with hypothesis formation. It is a valuable third layer. But it cannot function without the analytical and predictive foundation underneath it. The pyramid runs from the bottom up, not the top down.

The pyramid runs from the bottom up. Generative AI cannot function without the analytical and predictive foundation underneath it. But the funding, the headlines, and the enterprise budgets flow from the top.

Why Large, Messy Data Is Where This Matters Most

The Labcorp platform is built on a specific problem that exists across healthcare, climate science, infrastructure management, and financial risk: data that is large, fragmented, siloed by regulatory constraint, and nearly impossible to join without specialized infrastructure. Labcorp holds diagnostic and genomic data. Medical insurers hold claims data. Hospitals hold electronic health records. Social services agencies hold data on housing, food access, and income. Each dataset is meaningful in isolation. Combined, they become predictive.

The technical problem that has blocked that combination is privacy. Datavant solves this with token-based de-identification: patients are assigned pseudonymous tokens that allow records to be linked across institutions without ever exposing identifiable information. That infrastructure is why Labcorp can join its lab results to claims data without a HIPAA violation. It is not glamorous. It does not generate press releases about transforming creativity. But it is the infrastructure layer that makes the AI useful.

This is the pattern I keep observing in enterprise AI deployments that actually change outcomes: the AI itself is not the bottleneck. The bottleneck is data access, data quality, and the infrastructure to join datasets that were never designed to talk to each other. When that infrastructure problem is solved, even modestly capable Analytical and Predictive AI models produce results that look like breakthroughs — because the comparison is against humans doing the same work with spreadsheets and six months of time.

What AWS Is Actually Building

The Labcorp platform was announced on April 14, 2026, the same day as Amazon Bio Discovery — AWS's drug discovery service that routes candidate molecules to physical contract research laboratories and returns results automatically. I covered that launch and argued that the cloud just acquired a wet floor.

The date alignment is not a coincidence. AWS is building both ends of the drug development data supply chain simultaneously. Amazon Bio Discovery handles upstream discovery: hypothesis, model selection, physical synthesis, results. The Labcorp platform handles downstream real-world evidence: what actually happened to patients who received treatments, across millions of cases, across years of follow-up data.

Amazon Bedrock is the agentic layer connecting both. Amazon SageMaker runs the analytical workloads at scale. The infrastructure argument is straightforward: once pharma research runs on AWS at both ends of its pipeline, migrating off becomes a data gravity problem, not a contract negotiation.

That is a Clawconomy play. The autonomous AI agent infrastructure economy runs on whoever owns the data layer, the compute layer, and the orchestration layer at the same time. AWS is assembling all three inside life sciences.

The Expansion Roadmap Is the Real Signal

The Alzheimer's platform is in initial validation through spring 2026. The announced expansion covers inflammatory diseases, cardiometabolic conditions, women's health, and oncology — all by end of 2026. That is not a product roadmap. That is a data monetization roadmap.

Labcorp's business model has historically been fee-for-service laboratory testing. Each disease expansion converts a new segment of Labcorp's existing diagnostic dataset into a recurring analytical product sold to biopharma sponsors, contract research organizations, and payors. The underlying lab work already happened and was already paid for. The AI platform is a second revenue event on the same data asset.

That business model shift — from transactional testing to recurring data product — is the structural story. The speed claim (months to minutes) is the marketing wrapper around a more fundamental change in how Labcorp creates value from its diagnostic infrastructure.

What Enterprise Leaders Should Take From This

Most enterprise AI investment conversations start with Generative AI use cases: summarization, content generation, internal chatbots. Those use cases have real value. But the highest-return AI investments in the next three years will go to organizations that first solve their data access and data quality problems, then layer Analytical and Predictive AI on top of clean, joined datasets, and use Generative AI last as the interface layer that makes findings actionable.

The question every CIO and CTO should be asking is not "what can we do with a large language model?" It is: "what data do we own that we cannot currently analyze at scale, and what would Analytical and Predictive AI find if we could?"

Labcorp had the data for decades. The platform is new. The value was always there, locked in fragmented, siloed form. That is true in every industry. The organizations that unlock it first will not make headlines for doing something creative. They will make headlines for finding things nobody knew were there.

About Shashi Bellamkonda

Loading bio…

LinkedIn Profile

Get new posts by email:

Subscribe

Powered by